E2F2 and prostate carcinoma: Given that prostate cancer is a highly heterogeneous tumor, somatic mutations of clinicopathologically significant E2Fs, including the E2F1, E2F2, E2F3, E2F5, and E2F6, were further investigated in PCa patients.